International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8228912
Original Article
Neurological Manifestations of Community Acquired Staphylococcus Aureus Infection- A Case Series
 ,
 ,
Published
Aug. 6, 2023
Abstract

Background: Community acquired Staphylococcus Aureus causing neurological manifestations is rare. Very few reports document presentations and outcomes of this disease. We present, a series of 4 patients with neurological manifestations of spontaneous community acquired Staphylococcal Aureus admitted to an adult intensive care unit (ICU)over one year period. Patterns of community acquired Staphylococcal Aureus related neurological manifestations, from different regions are needed to draft evidence based management guidelines.

Objectives: To document clinical, laboratory and radiological findings in a cohort of community acquired Staphylococcal Aureus patients hospitalised with neurological manifestations and compare their presentation and outcomes with previously published cases available.

Study design: Clinical, laboratory, demographic information and outcomes were collected from patients with confirmed CNS infections of community acquired Staphylococcal Aureus treated in an ICU, in a tertiary care hospital, from September 2021- August 2022.

Results: The case series had a male predominance(75%) and the mean age was 61.3 yrs. All 4 patients were diabetics.75% had an epidural abscess but none had features of infective endocarditis. All patients were positive for MRSA in blood and pus. They were treated with parenteral Vancomycin and surgical decompression whenever indicated. Out of the 4 patients 2 improved and were discharged, 1 patient was transferred to another centre and 1 patient died.

Conclusion: Awareness of neurological manifestations of community acquired Staphylococcal Aureus should allow its early recognition and institution of appropriate treatment. Reports on community acquired Staphylococcal Aureus, from different regions will help in formulating more evidence-based guidelines, for optimum evaluation and care of such patients. Our data contributes towards this goal.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
1311 Views
10 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved